罢免案被否！盟科药业将迎“久违”实控人

Core Points - The control dispute over Mengke Pharmaceutical (688373) has been resolved, with a significant capital increase plan of approximately 1.033 billion yuan approved, allowing Nanjing Haiqing Pharmaceutical to become the controlling shareholder [2][3] - The proposal to dismiss the chairman and three directors by the largest shareholder, Genie Pharma, was rejected, indicating a shift in governance [2][3][5] Group 1: Shareholder Meeting Outcomes - The capital increase plan received overwhelming support, with over 81% approval for key resolutions, including the issuance of shares and the introduction of strategic investors [3][4] - The voting results showed that approximately 323 million shares (81.73%) supported the proposal to issue shares to specific investors [4][5] - The participation rate in the shareholder meeting was high, with 438 attendees representing 60.41% of the total shares [8] Group 2: Financial Performance and Future Prospects - Mengke Pharmaceutical has been in a loss-making state, with cumulative losses exceeding 1.3 billion yuan from 2021 to 2024, despite a revenue increase of 10.26% in the first half of 2025 [9] - The introduction of Haiqing Pharmaceutical as a strategic investor is expected to enhance Mengke's commercialization capabilities and address production capacity issues [14] - Haiqing Pharmaceutical has shown steady growth, with revenues increasing from 486 million yuan in 2022 to 648 million yuan in 2024, and a net profit of 104 million yuan in 2024 [9][11]